Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Zelenetz, Andrew D., Salles, Gilles, Mason, Kylie D., Casulo, Carla, Le Gouill, Steven, Sehn, Laurie H., Tilly, Herve, Cartron, Guillaume, Chamuleau, Martine E. D., Goy, Andre, Tam, Constantine S., Lugtenburg, Pieternella J., Petrich, Adam M., Sinha, Arijit, Samineni, Divya, Herter, Sylvia, Ingalla, Ellen, Szafer-Glusman, Edith, Klein, Christian, Sampath, Deepak, Kornacker, Martin, Mobasher, Mehrdad, Morschhauser, Franck
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497517/
https://ncbi.nlm.nih.gov/pubmed/30850381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-880526
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi